Experience In Using PBPK Models in Clinical Pharmacology Reviews

More documents

Recommendations

Info

Renal Impairment on Non-renally Eliminated Drugs Compound (% CL by kidney) Sildenafil (
The Need to Consider Metabolites in RI or DDI Targeted by RI? Assuming UK103320 is solely metabolized by CYP3A4 AUCR of UK103320 Severe RI Inhibition Obs. 3.0 a 1.4 b Pred. 2.5 5.2 a . Muirhead. Br. J.Clin.Pharmacol. 2002, with renal impairment b . Muirhead. Br.J.Clin.Pharmacol. 2002, using erythromycin Zhao P, et al, J Clin Pharmacol, 2012 � Over-predicted DDI: knowledge gap in metabolite disposition? 35
Page 1 and 2: Experience In Using PBPK Models in
Page 3 and 4: Physiologically-based Pharmacokinet
Page 5 and 6: C C a,V a C, V Can Model Provide De
Page 7 and 8: �Central role: to assess PKPD in
Page 9 and 10: Outline � Why PBPK � Applicatio
Page 11 and 12: Interacting drug ADME, PK, PD and M
Page 13 and 14: Fesoterodine case Polymorphic vs No
Page 15 and 16: Organ Dysfunction: The Interplay Ef
Page 17 and 18: PBPK Simulation: Renal Impairment +
Page 19 and 20: DDI Caused by Dose- and Time-depend
Page 21 and 22: Study Design Should inhibitor and s
Page 23 and 24: Model-based Design of Clinical PK S
Page 25 and 26: Pediatrics Geriatrics Pregnancy The
Page 27 and 28: Clearance Prediction Needs To Be Ta
Page 29 and 30: PBPK model in adults PBPK model in
Page 31 and 32: Basic steps for PBPK analyses 0. De
Page 33: Acknowledgements FDA Office of Clin

Experience In Using PBPK Models in Clinical Pharmacology Reviews

Create successful ePaper yourself

Delete template?

Save as template?